Damora Therapeutics Inc (NASDAQ: DMRA) is a clinical-stage biopharmaceutical company developing biological product candidates for undisclosed disease indications. The company has generated no revenue from product sales since inception, as disclosed in its 10-K filed March 19, 2026. Operations are funded entirely through equity financing, including Series B and Series C non-voting convertible preferred stock and common stock. Its pipeline consists of three named candidates: DMR-001, DMR-002, and DMR-003, all in preclinical or early clinical development as of December 31, 2025. The company relies on contract manufacturing organizations (CMOs) and contract research organizations (CROs) for manufacturing and clinical trial execution. With an accumulated deficit on its balance sheet and no near-term product revenue expected, Damora is a pre-commercial, capital-dependent biotech dependent on continued external financing to advance its programs through regulatory approval.

Revenue model

No product revenue as of December 31, 2025. The company has generated no revenue from product sales since inception and funds operations through equity capital raises.

Products and services

Three biological product candidates in development: DMR-001, DMR-002, and DMR-003. No products are approved or commercialized as of the 10-K filed March 19, 2026.

Customers and end markets

No commercial customers as of December 31, 2025. End markets are not specified in the filing excerpts provided.

Value-chain role

Drug developer outsourcing manufacturing to CMOs and clinical trial management to CROs. Pre-commercial; no sales, marketing, or distribution infrastructure in place as of the filing date.

Geographic exposure

Primary regulatory focus on the United States (FDA). The company acknowledges subject to regulations in other jurisdictions but no specific geographic markets are identified in the filing excerpts.

Source: SEC 10-K, filed 2026-03-19

Industry: Pharmaceutical Preparations Peers: Evaxion A/S Forward Pharma A/S IO Biotech Inc